Altasciences is a forward-thinking, mid-size contract research organization offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services.
A MESSAGE FROM OUR CEO
Imagine partnering with an integrated team that you trust, and telling your story once. Imagine a world where everyone and every project is of equal importance. Just imagine…
For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions.
Our integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements.
Our shared goal: to help you make educated, faster and more complete early phase drug development decisions — to speed you to proof of concept and beyond.
OUR UNIQUE APPROACH
At Altasciences, we provide you with clear, customized roadmaps, supported by our real-time data generation, proprietary communication platform, and central program management and scheduling to help you get to clinical proof of concept, faster.
Our purpose is to help you research and develop potentially life-saving therapeutics — and get you there faster, with integrated CRO/CDMO services, always moving in unison for maximum efficiency.
Altasciences has strategically placed research and manufacturing facilities across North America.
Our clinical trial facilities include adaptive Phase 1 and 2 clinical pharmacology units for healthy normal participant and patient population studies, as well as capabilities for specialized assessments such as driving simulation, human abuse potential, for large and small molecules.
Our preclinical research facilities include 250,000 square feet of purpose-built space, where we conduct comprehensive regulatory safety testing, bioanalysis, and other research support services in a wide range of species for both small and large molecules.
We have state-of-the-art bioanalytical laboratories, including LC-MS/MS and a dedicated ligand binding large molecule lab, with over 200 specialized analysts available 24/7, according to program needs. We use the latest equipment, technologies, and advanced methods, and have the capacity to process over 60,000 study samples per month.
Our 64,000 square-foot CDMO formulation, manufacturing and analytical campus includes an analytical lab, R&D formulations lab, multiple manufacturing suites including segregated and dedicated Schedule I and potent handling capabilities, and warehouse space.
Founded as Algorithme Pharma
Built clinical site and bioanalytical laboratory, Montréal, Quebec
First contract with a US-based biotech company
Passed first inspection by US FDA
Inaugurated HQ and new bioanalytical lab in Laval, Quebec
New clinical site opened in Montréal, Quebec
Chris Perkin appointed President and Chief Executive Officer
Became Altasciences and acquired Vince & Associates Clinical Research in Kansas City, KS
Expanded research campus in Kansas City, KS
Acquired preclinical safety testing business in Seattle, WA
Acquired manufacturing and analytical services facility in Philadelphia, PA
Acquired clinical pharmacology unit in Los Angeles, CA
Expanded manufacturing and analytical facility in Philadelphia, PA
Acquired preclinical testing laboratory in Scranton, PA
Acquired preclinical testing facility in Columbia, MO
OUR EXECUTIVE TEAM
Chris became CEO of Altasciences in 2010. He began his career at Huntingdon Life Sciences in England in 1975 as a toxicologist. He served as Section Head for preclinical development at Beecham Pharmaceuticals, as COO for CTBR Bio-Research in Montreal and then as SVP for Charles River Laboratories, responsible for seven preclinical facilities in the U.S., Canada, and China.
BS in Biology
Cathy joined us in 2010 with the mandate of transforming our commercial offering to cater to the expanding innovator market, and now oversees our commercial strategy, including M&A activity. She started her career at CTBR Bio-Research Inc. (now Charles River Laboratories) and served as Senior Site Director of its Montreal facility.
BA in Psychology, MBA
Dr. Setnik joined Altasciences in 2019. In her previous roles as Vice President of Scientific & Medical Affairs at INC Research/Syneos Health (Early Phase), Senior Director, Clinical Sciences (King Pharmaceuticals and Pfizer, Inc), and Research Scientist (formerly Ventana / Decisionline Clinical Research) she has accumulated impressive experience in early phase clinical trials, regulatory filing, lifecycle management, and strategic initiatives in business development and clinical drug development. Dr. Setnik is also an Adjunct Professor at the University of Toronto, Department of Pharmacology and Toxicology and the Managing Director lead of the Cross Company Abuse Liability Council and chair of the Clinical Pharmacology Community of the Drug Information Association (DIA). She is also an active member and speaker at various congresses including the College on Problems of Drug Dependence; and is actively engaged in many aspects of abuse potential assessment including development of patient reported outcome instruments and contributing to post-marketing surveillance studies.
PhD in Pharmacology and the Collaborative Program in Neuroscience
Dr. Morelli is a member of the College of Physicians of Québec, Canada, with over 30 years' medical experience and over 20 years' global clinical research background. He joined Altasciences in 2013, as a GI consultant and then as Medical Advisor, followed by Clinical PI and now Chief Medical Officer. Prior to joining Altasciences, Dr. Morelli was the Global Medical Director at MDS Pharma for 10 years, overseeing five clinical sites in Canada, the U.S.A., and Ireland. Dr. Morelli is an Associate Professor of Medicine at McGill University Montreal. He also continues to be active staff at the McGill University Hospital Center. In addition, he is Director of Gastroenterology/GI Endoscopy at one of the McGill University affiliated hospitals. He has been lead Principal Investigator in numerous multi-national, multi-center clinical trials.
Steve is responsible for all of our preclinical and clinical pharmacology sites. He started as a toxicologist for Huntingdon Life Sciences. At CTBR Bio-Research (now Charles River Laboratories) in Montreal, he built the Safety Pharmacology Department, and then moved to China to establish the Charles River Shanghai preclinical facility, which became the first non-clinical facility in China to be certified as OECD GLP compliant. He joined WuXi AppTec in Suzhou, China, as VP of Preclinical Services, before coming to Altasciences in 2014.
BS in Biological Sciences, MS in Toxicology
Marie-Hélène oversees all of our Research Services, including Data Management, Biostatistics, Project Management, and Medical Writing. She started her career as a Business Development Manager at Future Electronics. At Charles River Laboratories, she rose to become Global Director of Marketing, before joining Altasciences in 2012.
BA in Psychology, Exec MBA
David started his career in 2000 as a Quality Assurance Inspector at CTBR Bio-Research (now Charles River Laboratories). At Pharmascience, he developed and implemented a GxP quality system for both bioanalytical and clinical operations. David has been a member of the Board of Directors of the Canadian Chapter of the Society of Quality Assurance, and served as VP and then President. He joined Altasciences in 2012.
BS in Biology
Julie-Ann joined Altasciences in 2014 to lead business development for our Kansas City site’s operations. In 2016, she was promoted to Vice President, Business Development and in 2017, was appointed to her current position. She began her career in 1998 at Origenix Technologies, a biotech company in Montreal. In 2003, she moved to CTBR Bio-Research (now Charles River Laboratories) where she progressed to Head of Marketing. In 2008, she was seconded to China as Director of Business Development for Charles River Laboratories Shanghai, and then served as Head of Global Marketing for the Charles River Laboratories Preclinical Division. In 2011, she joined WuXi AppTec in Suzhou, China, as Executive Director of Business Development for Preclinical Services, managing staff in China and the U.S.
BS in Exercise Science (Kinesiology), MBA
Robert oversees all of our business development activities. He joined Altasciences in 2012, focusing initially on the growth of our bioanalysis business. Prior, he worked at Charles River Laboratories as a Regulatory Inspector, where he oversaw the Bioanalytical Preclinical segment and managed government audits. He also spearheaded the training and process development programs for the Quality Assurance departments in several site locations. When he joined Altasciences, he transitioned to Business Development, with responsibilities that included key global account oversight.
BS in Physiology, Graduate Diploma in Business Administration
Mariano started his career with Ernst & Young in 1991 before joining Phoenix International as Global Director of Finance where he completed eight acquisitions. Subsequently, he held a number of Chief Financial Officer positions with various companies, including Galileo Genomics, Neurochem, and GFI Solutions. Most recently, Mariano was the Chief Operating Officer and Chief Financial Officer for Klox Technologies. He joined Altasciences in 2018.
B. Commerce, Graduate Degree in Public Accountancy, CPA CA, CPA USA
Recognized by the industry, Altasciences has the leadership, scientific, and operational excellence you need to move your programs from lead candidate selection to clinical proof of concept, and beyond.
Citeline Awards 2021 Finalist in Best Sponsor-Facing Technology Initiative
Pharma Tech Outlook Top 10 CROs
Most Successful Early Phase Research (Preclinical and Phase I)
February 2018, 2017, 2016, 2015, 2014
CRO Leadership Awards (Multiple Categories)
Pharma Tech Outlook Top 10 CROs
August 2018, 2017, 2016, 2015
PharmaVOICE 100 Most Inspiring Leaders in the Life Sciences Industry - Chris Perkin, CEO
Finalist - Most Successful Early Phase Research (Preclinical & Phase I) Clinical and Research Excellence (CARE) Awards by Pharma Intelligence
Full-Service Early Stage Clinical Research Provider of the Year Gamechangers™️ Healthcare / Pharmaceutical / Biotech and Medtech Awards 2018
Gamechanger of the Year - Chris Perkin, CEO. Gamechangers™️ Healthcare / Pharmaceutical / Biotech and Medtech Awards 2018
Best Early Phase CRO in North America Global Health and Pharma (GHP) 2018 Biotechnology Awards
Scrip Award for Best CRO - Niche
Most Innovative in Biotech TMT News
Best Full-Service Early Stage Clinical Research Provider in Canada Global Health and Pharma (GHP) 2016 Biotechnology Awards
Annual Canada Awards for Excellence
Grands Prix Québécois de la Qualité
We partner with biotech and pharmaceutical companies of every size and spend, from startups to global leaders. Our client portfolio is deep, international, diverse — and working at the forefront of medical science.
The devotion, expertise, and degree of professionalism employed by the (Altasciences) team in all stages of development, and the support provided during the Clinical trial, were unprecedented.
The professionalism and skills (of Altasciences) ... were crucial to the success of our efficacy program... delivered with time and cost efficiencies. Their expertise in Bioanalytical development and method validation has proven to be added value...
Our people take pride in engaging in the communities where we work and live. Initiatives include Dare to Give breast cancer fundraising, our school supplies campaign, Holiday gift drives for kids, food and winter clothing drives, as well as other ways of giving back. We reflect our passion, commitment, and dedication in everything we do, from our community involvement to our work.
COMMITMENT TO PARTICIPANTS
We value the people who participate in our clinical trials and contribute to advancing medical science. We, in turn, provide a safe, comfortable, and caring study environment. We treat all our participants respectfully, with transparency and openness, at the initial recruiting and screening process, and throughout the trial period.
FOCUS ON ANIMAL WELFARE
We maintain an unwavering focus on the welfare of the laboratory animals in our care. Our entire preclinical staff is trained in laboratory animal care and focused on animal welfare and environmental enrichment—embracing compassion, sensitivity and adherence to regulatory guidelines.
With each quarter comes an opportunity for our CEO, Chris Perkin, to reflect on the past, the present, and the future of Altasciences. Read Chris’ special message to you.